| ORIGINAL ARTICLE |
|
| Year : 2016 | Volume
: 12
| Issue : 1 | Page : 238-243 |
|
|
Survival and prognostic factors in limited stage small cell lung cancer: A retrospective study from northeast Turkey
Özlem Aynaci, Emine Canyilmaz, Lasif Serdar, Mustafa Kandaz, Zümrüt Bahat, Adnan Yoney
Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
Correspondence Address:
Özlem Aynaci
Karadeniz Technical University, Faculty of Medicine, Department of Radiation Oncology, Trabzon - 61080
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.151446
|
|
|
Aim of the Study: The purposes of this retrospective study were to identify survival rates for limited stage small cell lung cancer (LD-SCLC) and analyze treatment outcomes and influencing factors on survival.
Materials and Methods: We conducted data from patients diagnosed with LD.SCLC between January 1998 and December 2012 at our institution. Dermographic information, treatment modalities, pretreatment clinical asessment, were recorded. Most of the patients. (88.4%) were treated with curative intent. The survival probabilties were asessed by Kaplan.Meier analysis. Cox regression was used to assess prognostic factors on overall survival and disease.free survival.
Results: A total of 129 patients were examined as a LD-SCLC. The median age was 60 (range; 31–86). Median follow-up time was 9.4 (SE ± 20.5) months and the median overall survival was 13.9 months [95% cumulative incidence (CI): 10.1–17.6]. On multivariate analysis, concurrent chemotherapy [HZ: 2.7 (95% CI: (1.0–7.2)] (P = 0.037) and doses of radiation therapy (<50, ≥50) [HZ: 1.4 (95% CI: (1.0–2.2)] (P = 0.046) were statistically significant on overall survival. With regard to multivariate anlaysis age (<60, ≥60) [HZ: 2.2 (95% CI: (0.6–3.7)] (P = 0.011), doses of radiation therapy (<50, ≥50) [HZ: 2.7 (95% CI: (1.0–7.2)] (P = 0.046), precense of surgery [HZ: 15.3 (95% CI: (1.5–152)] (P = 0.020), prophilactic cranial radiation therapy (PCI) [HZ: 2.3 (95% CI: (1.1–4.5)] (P = 0.014), and presence of concurrent chemoradiotherapy [HZ: 3.0 (95% CI: (1.3–6.8)] (P = 0.008) were important variable affecting disease-free survival.
Conclusion: For LD-SCLC patients concurrent chemoradiation therapy and 50. Gy and over doses radiation therapy provided improvement on overall and disease.free survival. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
